Commonwealth Equity Services LLC trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 4.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 189,112 shares of the biopharmaceutical company's stock after selling 8,925 shares during the quarter. Commonwealth Equity Services LLC owned 0.12% of TG Therapeutics worth $5,692,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in TGTX. State Street Corp lifted its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Principal Financial Group Inc. raised its position in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after purchasing an additional 725,371 shares during the period. Raymond James Financial Inc. purchased a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $14,508,000. Braun Stacey Associates Inc. bought a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $13,328,000. Finally, Castellan Group purchased a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $8,539,000. Institutional investors own 58.58% of the company's stock.
Analyst Ratings Changes
Several equities analysts have commented on TGTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.
Read Our Latest Report on TGTX
Insider Buying and Selling at TG Therapeutics
In related news, CFO Sean A. Power sold 11,337 shares of the firm's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company's stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 10.50% of the company's stock.
TG Therapeutics Stock Down 4.7 %
Shares of TGTX stock traded down $2.01 on Wednesday, hitting $40.79. The stock had a trading volume of 2,324,143 shares, compared to its average volume of 2,981,159. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $43.32. The business has a 50 day moving average price of $33.73 and a 200 day moving average price of $30.03. The company has a market cap of $6.41 billion, a PE ratio of -407.86 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Stories
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
